eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
1/2016
vol. 8
 
Share:
Share:
more
 
 
abstract:
Original paper

Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses

Rosa Ballester-Sánchez, Olga Pons-Llanas, Cristian Candela-Juan, Francisco Javier Celada-Álvarez, Christopher A. Barker, Alejandro Tormo-Micó, Jose Pérez-Calatayud, Rafael Botella-Estrada

J Contemp Brachytherapy 2016; 8, 1: 48–55
Online publish date: 2016/01/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose: Basal cell carcinoma (BCC) is a very common cancer in the Caucasian population. Treatment aims to eradicate the tumor with the lowest possible functional and aesthetic impact. Electronic brachytherapy (EBT) is a treatment technique currently emerging. This study aims to show the outcomes of two consecutive prospective pilot clinical trials using different radiation doses of EBT with Esteya® EB system for the treatment of superficial and nodular basal cell carcinoma.

Material and methods: Two prospective, single-center, non-randomized, pilot studies were conducted. Twenty patients were treated in each study with different doses. The first group (1) was treated with 36.6 Gy in 6 fractions of 6.1 Gy, and the second group (2) with 42 Gy in 6 fractions of 7 Gy. Cure rate, acute toxicity, and late toxicity related to cosmesis were analyzed in the two treatment groups.

Results: In group 1, a complete response in 90% of cases was observed at the first year of follow-up, whereas in group 2, the complete response was 95%. The differences with reference to acute toxicity and the cosmetic results between the two treatment groups were not statistically significant.

Conclusions: Our initial experience with Esteya® EB system to treat superficial and nodular BCC shows that a dose of 36.6 Gy and 42 Gy delivered in 6 fraction of 7 Gy achieves a 90% and 95% clinical cure rate at 1 year, respectively. Both groups had a tolerable toxicity and a very good cosmesis. The role of EBT in the treatment of BCC is still to be defined. It will probably become an established option for selected patients in the near future.
keywords:

basal cell carcinoma, electronic brachytherapy, radiation therapy, skin cancer

references:
Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg 2007; 11: 19-30.
Roozeboom MH, Arits AH, Nelemans PJ et al. Overall treatments success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-analysis of ran­domized and nonrandomized trials. Br J Dermatol 2012; 167: 733-756.
Candela-Juan C, Niatsetski Y, Ouhib Z et al. Commissioning and periodic tests of the Esteya® electronic brachytherapy system. J Contemp Brachytherapy 2015; 7: 189-195.
Bhatnagar A. Electronic brachytherapy for the treatment of non-melanoma skin cancer: results up to 5 years. Proceedings of the 73th annual meeting of the American Academy of Dermatology; 2015 March 20-24; San Francisco, USA.
Dogget S, Willoughby M, Mafong E et al. Electronic bra­chytherapy for non-melanoma skin cancer: report of first 565 lesions. Proceedings of the 73th annual meeting of the American Academy of Dermatology; 2015 March 20-24; San Francisco, USA.
Strimling RB, Jones CL, Schaeffer J et al. Initial experience of electronic brachytherapy for the treatment of 494 non-melanoma skin cancer (NMSC) lesions in 297 patients. Proceedings of the 73th annual meeting of the American Academy of Dermatology; 2015 march 20-24; San Francisco, USA.
Paravati AJ, Hawkins PG, Martin AN et al. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol 2015; 5: 659-664.
Linos E, Van Beek M, Resneck JS. A sudden and concerning increase in the use of electronic brachytherapy for skin cancer. JAMA Dermatol 2015; 151: 699-700.
Ouhib Z, Kasper M, Perez Calatayud J et al. Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report. Brachy­therapy 2015; 14: 840-858.
Tormo A, Celada F, Rodriguez S et al. Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes. J Contemp Brachytherapy 2014; 6: 167-172.
Jones B, Dale RG, Deehan C et al. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) 2001; 13: 71-81.
Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101: 1623-1631.
Pötter R, Haie-Meder C, van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy – 3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, and radiobiology. Radiother Oncol 2006; 78: 67-77.
Trott KR, Maciejewski B, Preuss-Bayer G et al. Dose-response curve and split-dose recovery in human skin cancer. Radio­ther Oncol 1984; 2: 123-129.
Pons-Llanas O, Ballester-Sánchez R, Celada-Álvarez FJ et al. Clinical implementation of a new electronic brachytherapy system for skin brachytherapy. J Contemp Brachytherapy 2014; 6: 417-423.
Food and Drug Administration (FDA). Avoidance of serious x-ray-induced skin injuries to patients during fluoroscopically-guided procedures. Fed Regist 1994; 59: 26402-26405.
Reniers B, Liu D, Rusch T et al. Calculation of relative effectiveness of a low-energy electronic brachytherapy source. Phys Med Biol 2008; 53: 7125-7135.
Bistrović M, Bišćan M, Viculin T. RBE of 20 kV and 70 kV X-rays determined for survival of V 79 cells. Radiother Oncol 1986; 7: 175-180.
Brenner DJ, Leu CS, Beatty JF et al. Clinical relative bio­logical effectiveness of low-energy x-rays emitted by miniature x-ray devices. Phys Med Biol 1999; 44: 323-333.
Verhaegen F, Reniers B. Microdosimetric analysis of various mammography spectra: lineal energy distributions and ionization cluster analysis. Radiat Res 2004; 162: 592-599.
Kühne M, Urban G, Frankenberg D et al. DNA double-strand break misrejoining after exposure of primary human fibroblasts to CK characteristic X rays, 29 kVp X rays and 60Co gamma rays. Radiat Res 2005; 164: 669-676.
Mestres M, Caballín MR, Barrios L et al. RBE of X rays of different energies: a cytogenetic evaluation by FISH. Radiat Res 2008; 170: 93-100.
Bernal MA, de Almeida CE, David M et al. Estimation of the RBE of mammography-quality beams using a combination of a Monte Carlo code with a B-DNA geometrical model. Phys Med Biol 2011; 56: 7393-7403.
Flickinger JC. A radiobiological analysis of multicenter data for postoperative keloid radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 1164-1170.
García-Martínez T, Chan JP, Perez-Calatayud J et al. Dosimetric characteristics of a new unit for electronic skin bra­chytherapy. J Contemp Brachytherapy 2014; 6: 45-53.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
Ballester-Sánchez R, Pons-Llanas O, Llavador-Ros M et al. Depth determination of skin cancers treated with superficial brachytherapy: ultrasound vs histopathology. J Contemp Brachytherapy 2014; 6: 356-361.
Ballester-Sánchez R, Pons-Llanas O, Pérez-Calatayud J et al. Dermoscopy margin delineation in radiotherapy planning for superficial or nodular basal cell carcinoma. Br J Dermatol 2014; 172: 1162-1163.
CTCAE v4.0: NIH Publication No. 09-5410.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
Bath-Hextall FJ, Perkins W, Bong J et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 24: CD003412.
Avril MF, Auperin A, Margulis A et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997; 76: 100-106.
Delishaj D, Manfredi B, Laliscia C et al. Non-melanoma skin cancer treated with HDR Brachytherapy and Valencia applicator in elderly patients. Eur J Cancer 2015; 51: S669.
Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C et al. Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy 2015; 7: 231-238.
Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy 2013; 12: 134-140.
Ghaly M, Zinkin H, Dannenberg M et al. HDR brachytherapy with standardized surface applicators in the treatment of superficial malignant skin lesions. Int J Radiat Oncol Biol Phys 2008; 72: 505-506.
Gauden S, Egan C, Pracy M. HDR brachytherapy for the treatment of the skin cancer using standard surface applicators. Brachytherapy 2008; 7: S159.
Amendola BE, Amendola MA, Fowler J. Dermatological applications of HDR using surface applicators using a shorter treatment schedule. Brachytherapy 2006; 5: S106.
Fabrini MG, Perrone F, De Liguoro M et al. High dose rate brachytherapy in a large squamous cell carcinoma of the hand. Brachytherapy 2008; 7: 270-275.
Kohler-Brock A, Prager W, Pohlmann S et al. The indications for and results of HDR afterloading therapy in diseases of the skin and mucosa with standardized surface applicators (the Leipzig Applicator). Strahlenther Onkol 1999; 175: 170-174.
 
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe